Rao Karthik N, Sreeram M P, de Bree Remco, Mendenhall William M, Strojan Primož, Stenman Göran, Mäkitie Antti, Nadal Alfons, Rodrigo Juan P, Ng Sweet Ping, Corry June, Rinaldo Alessandra, Eisbruch Avraham, Ferlito Alfio
Department of Head and Neck Oncology, Sri Shankara Cancer Foundation, Bangalore 560004, India.
Department of Head and Neck Surgical Oncology, Division of Imaging and Oncology Center, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands.
Cancers (Basel). 2025 Mar 3;17(5):862. doi: 10.3390/cancers17050862.
To evaluate the impact of postoperative radiotherapy (PORT) on oncological outcomes in node-negative early-stage oral squamous cell carcinoma (OSCC) with perineural invasion (PNI). : A systematic review and meta-analysis was conducted using the PubMed, EMBASE, and Scopus databases for the period from 2000 to 2024. Studies comparing PORT versus observation in pN0 early-stage OSCC with PNI were included. Oncological outcomes assessed included overall survival (OS), disease-free survival (DFS), and local control (LC). A random-effects model was used to calculate log odds ratios, and heterogeneity was assessed using tau, chi, and I statistics. : Seven retrospective studies comprising 522 patients (281 PORT, 241 no-PORT) were included. The 3-year overall survival (OS) was 86.3% in the PORT group compared to 71.1% in the no-PORT group (logOR = -1.03, = 0.0012), while the 5-year OS was 88.1% versus 77.3% (logOR = -0.97, = 0.0061). Disease-free survival (DFS) also favored PORT, with 3-year DFS at 86.3% versus 58.1% (logOR = -1.19, < 0.001) and 5-year DFS at 86.3% versus 55% (logOR = -0.78, = 0.003). Local control (LC) was higher in the PORT group, with 3-year LC rates of 89% compared to 72.2% in the no-PORT group (logOR = -1.13, = 0.025). : PORT significantly improves OS, DFS, and LC in node-negative early-stage OSCC with PNI as the sole adverse feature.
评估术后放疗（PORT）对伴有神经周围侵犯（PNI）的淋巴结阴性早期口腔鳞状细胞癌（OSCC）肿瘤学结局的影响。：使用PubMed、EMBASE和Scopus数据库对2000年至2024年期间进行了系统评价和荟萃分析。纳入了比较PORT与观察治疗在伴有PNI的pN0早期OSCC中的研究。评估的肿瘤学结局包括总生存期（OS）、无病生存期（DFS）和局部控制（LC）。采用随机效应模型计算对数比值比，并使用tau、chi和I统计量评估异质性。：纳入了7项回顾性研究，共522例患者（281例接受PORT，241例未接受PORT）。PORT组的3年总生存率（OS）为86.3%，未接受PORT组为71.1%（对数比值比=-1.03，P=0.0012），而5年总生存率分别为88.1%和77.3%（对数比值比=-0.97，P=0.0061）。无病生存期（DFS）也有利于PORT，3年DFS分别为86.3%和58.1%（对数比值比=-1.19，P<0.001），5年DFS分别为86.3%和55%（对数比值比=-0.78，P=0.003）。PORT组的局部控制（LC）更高，3年LC率为89%，未接受PORT组为72.2%（对数比值比=-1.13，P=0.025）。：PORT可显著改善以PNI为唯一不良特征的淋巴结阴性早期OSCC的OS、DFS和LC。
